Clotting factor concentrate switching and inhibitor development in hemophilia A

Blood

Volumn 120, Issue 4, 2012, Pages 720-727

  Iorio, Alfonso ^a   Puccetti, Paolo ^b   Makris, Mike ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; IMMUNOGLOBULIN G ANTIBODY;

ANTIBODY RESPONSE; CLINICAL PRACTICE; DRUG SUBSTITUTION; FAMILY HISTORY; GENOTYPE; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RACE; REVIEW;

EID: 84864473291     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-378927     Document Type: Review

References (75)

1. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779. (Pubitemid 32497033)
2. Aledort LM. Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia a treatment. J Thromb Haemost. 2011;9(3):423-427.
3. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:c inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73(2):247-251.
4. EMA. Report of expert meeting on factor VIII products and inhibitor development. London: European Medicines Agency; 2007. Ref: EMEA/ CHMP/BPWP/123835/2006. http://www. emea.europa.eu/docs/en-GB/document-library/ Report/2009/11/WC500015512.pdf. Accessed Jun 14, 2012.
5. Darby SC, Keeling DM, Spooner RJD, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost. 2004;2(7):1047-1054.
6. Hay CRM, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor viii and ix inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006;133(6):591-605. (Pubitemid 43742773)
7. Hay CRM, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia a in the United Kingdom. Blood. 2011; 117(23):6367-6370.
8. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia a: a systematic review. Haemophilia. 2003;9(4):418-435. (Pubitemid 36874391)
9. Kempton CL. Inhibitors in previously treated patients: a review of the literature. Haemophilia. 2010;16(102):61-65.
10. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia a patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost. 2010;8(6): 1256-1265.
11. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors'Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia. 2008;14(4):671-684.
12. Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, Roosendaal G, Briët E, van den Berg HM. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A. Thromb Haemost. 1994;71(6):703- 706.
13. Lee CA, Lillicrap D, Astermark J. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors. Semin Thromb Hemostas. 2006;32(Suppl 2):10-14.
14. Astermark J, Oldenburg J, Escobar M, White GC, Berntorp E. The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica. 2005;90(7):924-931.
15. Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia. 2010; 16(102):66-70.
16. Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost. 2011;9(11):2180-2192.
17. Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med. 2009;360(16):1618-1627.
18. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Pub Health. 2005;95(Suppl 1):S144-S150. (Pubitemid 41033428)
19. Neugebauer B, Drai C, Haase M, et al. Factor VIII products and inhibitor development: concepts for revision of European regulatory guidelines. Haemophilia. 2008;14(1):142-144.
20. White GC, DiMichele D, Mertens K, et al. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the scientific subcommittee on factor VIII and factor IX. Thromb Haemost. 1999;81(3):462. (Pubitemid 29116621)
21. EMA. Guideline on clinical investigation of recombinant and human plasma-derived factor IX products. London: European Medicines Agency; 2011; EMA/CHMP/BPWP/144552/2009. http://www. ema.europa.eu/docs/en-GB/document- library/ Scientific-guideline/2011/08/WC500109691.pdf. Accessed June 14, 2012.
22. EMA. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. London: European Medicines Agency; 2011; EMA/CHMP/BPWP/144533/2009. http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2011/08/ WC500109692.pdf. Accessed June 14, 2012.
23. White GC, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (recombinate) in previously treated patients with hemophilia A. The recombinate previously treated patient study group. Thromb Haemost. 1997;77(4):660-667. (Pubitemid 27182960)
24. Schwartz R, Abildgaard C, Aledort L. Human recombinant DNA-derived antihemophilic factor (Factor VIII) in the treatment of hemophilia A. N Engl J Med. 1990;323(26):1800-1805.
25. Abshire T, Brackmann H. Recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - results of a multicenter, international study. Thromb Haemost. 2000;83(6):811-816. (Pubitemid 30411675)
26. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients. Semin Hematol. 2001;38(2 Suppl 4):44-51. (Pubitemid 32612098)
27. Tarantino MD, Collins PW, Hay CRM, et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004;10(5):428-437. (Pubitemid 39328049)
28. Recht M, Nemes L, Matysiak M, et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor V. Haemophilia. 2009;15(4):869-880.
29. Hill AB. Principles of Medical Statistics. New York: Oxford University Press; 1971.
30. Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV. Downregulation of CD40 signal and induction of TGF-β by phosphatidylinositol mediates reduction in immunogenicity against recombinant human factor VIII. J Pharm Sci. 2012;101(1):48-55.
31. Hermeling S, Schellekens H, Maas C, Gebbink MFBG, Crommelin DJA, Jiskoot WIM. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci. 2006;95(5):1084-1096. (Pubitemid 43723167)
32. Purohit VS, Middaugh CR, Balasubramanian SV. Influence of aggregation on immunogenicity of recombinant human factor VIII in hemophilia a mice. J Pharm Sci. 2006;95(2):358-371. (Pubitemid 43241978)
33. Pisal DS, Kosloski MP, Middaugh CR, Bankert RB, Balu-Iyer SV. Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia A mice. J Pharm Sci. 2012;101(6):2055-2065.
34. Tovey MG, Legrand J, Lallemand C. Overcoming immunogenicity associated with the use of biopharmaceuticals. Exp Rev Clin Pharmacol. 2011; 4(5):623-631.
35. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood. 1993;81(11):2925-2935. (Pubitemid 23162110)
36. Parker ET, Craddock HN, Barrow RT, Lollar P. Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia a mice pre sensitized to human factor VIII. J Thromb Haemost. 2004;2(4):605-611. (Pubitemid 40185684)
37. Tangri S, Mothé BR, Eisenbraun J, et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol. 2005;174(6): 3187-3196. (Pubitemid 40354020)
38. Peng A, Kosloski MP, Nakamura G, Ding H, Balu-Iyer SV. PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia a mice. AAPS J. 2012;14(1):35-42.
39. Selvaraj SR, Scheller AN, Miao HZ, Kaufman RJ, Pipe SW. Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispensable disulfide loop. J Thromb Haemost. 2012;10(10):107-115.
40. Moise L, Song C, Martin WD, Tassone R, De Groot AS, Scott DW. Effect of HLA DR epitope de-immunization of factor VIII in vitro and in vivo. Clin Immunol. 2012;142(3):320-331.
41. Peng B, Ye P, Blazar BR, et al. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia a mice. Blood. 2008;112(5):1662-1672.
42. Delignat S, Dasgupta S, André S, et al. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica. 2007; 92(10):1423-1426. (Pubitemid 350144163)
43. Peerlinck K, Arnout J, Di Giambattista M, et al. Factor VIII inhibitors in previously treated haemophilia a patients with a double virus-inactivated plasma derived factor viii concentrate. Thromb Haemost. 1997;77(1):80-86. (Pubitemid 27064973)
44. Manuel DG, Rosella LC. Commentary: assessing population (baseline) risk is a cornerstone of population health planning - looking forward to address new challenges. Int J Epidemiol. 2010; 39(2):380-382.
45. Visschers VHM, Meertens RM, Passchier WWF, de Vrie NNK. Probability information in risk communication: a review of the research literature. Risk Analysis. 2009;29(2):267-287.
46. Malenka DJ, Baron JA, Johansen S, Wahrenberger JW, Ross JM. The framing effect of relative and absolute risk. J Gen Intern Med. 1993;8(10):543-548. (Pubitemid 23312931)
47. Fischhoff B, Brewer T, Downs J. Communicating risks and benefits: an evidence-based user's guide. http://www.fda.gov/downloads/AboutFDA/ ReportsManualsForms/Reports/UCM268069.pdf. Accessed June 14, 2012.
48. Schünemann H, Oxman A, Higgins J, et al. Presenting results and "summary of findings" tables. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken, NJ: Wiley; 2011.
49. Behera M, Kumar A, Soares HP, Sokol L, Djulbegovic B. Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control. 2007;14(2): 160-166. (Pubitemid 46515152)
50. Reade MC, Delaney A, Bailey MJ, Angus DC. Bench-to-bedside review: avoiding pitfalls in critical care meta-analysis-funnel plots, risk estimates, types of heterogeneity, baseline risk and the ecologic fallacy. Crit Care. 2008;12(4):220.
51. Tugwell P, McGowan J. Finding information about the burden of disease. J Clin Epidemiol. 2006; 59(9):887-892. (Pubitemid 44163429)
52. Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med. 1998;17(17): 1923-1942. (Pubitemid 28425258)
53. Concato J, Horwitz RI, Feinstein AR, Elmore JG, Schiff SF. Problems of comorbidity in mortality after prostatectomy. JAMA. 1992;267(8):1077- 1082.
54. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood. 1988;71(2):344-348. (Pubitemid 18089520)
55. Colvin BT, Hay CR, Hill FG, Preston FE. The incidence of factor VIII inhibitors in the united kingdom, 1990-93. Inhibitor Working Party. United Kingdom Haemophilia Centre Directors Organization. Br J Haematol. 1995;89(4):908-910.
56. Kempton CL, Soucie JM, Abshire TC. Incidence of inhibitors in a cohort of 838 males with hemophilia a previously treated with factor VIII concentrates. J Thromb Haemost. 2006;4(12):2576-2581. (Pubitemid 44741551)
57. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al.Asudden increase in factor VIII inhibitor development in multitransfused hemophilia a patients in The Netherlands. Blood. 1993;81(8):2180-2186. (Pubitemid 23106736)
58. Peerlinck K, Arnout J, Gilles JG, Saint-Remy JM, Vermylen J. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost. 1993;69(2):115-118. (Pubitemid 23041179)
59. Giles A, Rivard G, Teitel J, Walker I. Surveillance for factor viii inhibitor development in the Canadian hemophilia a population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci. 1998;19(2):139-148.
60. Rubinger M, Lillicrap D, Rivard GE, et al. A prospective surveillance study of factor viii inhibitor development in the Canadian haemophilia a population following the switch to a recombinant factor VIII product formulated with sucrose. Haemophilia. 2008;14(2):281-286. (Pubitemid 351338688)
61. Rea C, Dunkerley A, Sørensen B, Rangarajan S. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain- deleted r-FVIII and back to full-length FVIII. Haemophilia. 2009;15(6):1237-1242.
62. Bacon CL, Singleton E, Brady B, et al. Low risk of inhibitor formation in haemophilia a patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor viii product (ADVATE). Haemophilia. 2011;17(3):407-411.
63. Singleton E, Smith J, Kavanagh M, Nolan B, White B. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII. Thromb Haemost. 2007;98(6):1188-1192. (Pubitemid 350244408)
64. Gouw SC, Bom JG van der Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the Canal cohort study. Blood. 2007;109(11):4648-4654. (Pubitemid 46827754)
65. Siegmund B, Pollmann H, Richter H, Orlovic M, Gottstein S, Klamroth R. inhibitor development against FVIII in previously treated patients with haemophilia a. a retrospective data collection [in German]. Hä mostaseologie. 2010;30(Suppl 1): S37-S39.
66. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007;109(11): 4693-4697. (Pubitemid 46827760)
67. Iorio A, Marcucci M, Makris M. Concentrate related inhibitor risk: is a difference always real? J Thromb Haemost. 2011;9(11):2176-2179.
68. Mannucci PM. Factor VIII inhibitors in previously treated hemophilic patients. J Thromb Haemost. 2011;9(11):2328-2329.
69. Aledort LM, Navickis RJ, Wilkes MM. Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII. J Thromb Haemost. 2011;9(11):2325-2327.
70. Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. BMJ. 1995;311(7020):1621-1625. (Pubitemid 26002712)
71. Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ. 2007;334(7589):349-351. (Pubitemid 46328045)
72. Makris M, Calizzani G, Fischer K, et al. EUHASS: the European Haemophilia Safety Surveillance System. Thromb Res. 2011;127(Suppl 2):S22-S25.
73. Ragni MV, Ojeifo O, Feng J, et al. Risk factors for inhibitor formation in haemophilia: a prevalent case-control study. Haemophilia. 2009;15(5): 1074-1082.
74. Committee on Strategies for Small-Number- Participant Clinical Research Trials, Board on Health Sciences Policy, Evans CH Jr, Ildstad ST, eds. Small Clinical Trials: Issues and Challenges. Washington, DC: National Academy Press; 2001.
75. EMA. Guideline on clinical trials in small populations. London: European Medicines Agency; 2006 Doc. Ref. CHMP/EWP/83561/2005. http:// www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/ WC500003615.pdf. Accessed June 14, 2012.